Orthocell Limited (ASX:OCC) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.
Just last week Orthocell delivered its initial clinical results using Celgro™ in dental study.
The study was designed to demonstrate that Celgro™ can be used as a barrier membrane to allow bone growth without competition from other connective tissue.
The halt will remain in place until the opening of trade on Wednesday 18th November 2015, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.